CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib

Abstract Cyclin D‐CDK4/6 are the first CDK complexes to be activated in the G1 phase in response to oncogenic pathways. The specific CDK4/6 inhibitor PD0332991 (palbociclib) was recently approved by the FDA and EMA for treatment of advanced ER‐positive breast tumors. Unfortunately, no reliable predi...

Full description

Bibliographic Details
Main Authors: Eric Raspé, Katia Coulonval, Jaime M Pita, Sabine Paternot, Françoise Rothé, Laure Twyffels, Sylvain Brohée, Ligia Craciun, Denis Larsimont, Véronique Kruys, Flavienne Sandras, Isabelle Salmon, Steven Van Laere, Martine Piccart, Michail Ignatiadis, Christos Sotiriou, Pierre P Roger
Format: Article
Language:English
Published: Springer Nature 2017-08-01
Series:EMBO Molecular Medicine
Subjects:
CDK4/6 inhibitors
breast cancer
cyclin‐dependent kinase 4
PD0332991
sensitivity biomarker
Online Access:https://doi.org/10.15252/emmm.201607084

Internet

https://doi.org/10.15252/emmm.201607084

Similar Items